Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AVNS

AVNS - Avanos Medical Inc Stock Price, Fair Value and News

$13.70+0.27 (+2.01%)
Market Closed

50/100

AVNS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

AVNS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVNS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVNS Price Action

Last 7 days

3.1%

Last 30 days

-9.4%

Last 90 days

16.6%

Trailing 12 Months

-5.3%

AVNS RSI Chart

AVNS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVNS Valuation

Market Cap

637.1M

Price/Earnings (Trailing)

-8.74

Price/Sales (Trailing)

0.91

EV/EBITDA

-30.65

Price/Free Cashflow

8.53

AVNS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVNS Fundamentals

AVNS Revenue

Revenue (TTM)

701.2M

Rev. Growth (Yr)

0.72%

Rev. Growth (Qtr)

1.74%

AVNS Earnings

Earnings (TTM)

-72.9M

Earnings Growth (Yr)

99.67%

Earnings Growth (Qtr)

7.14%

AVNS Profitability

EBT Margin

-9.44%

Return on Equity

-9.37%

Return on Assets

-6.79%

Free Cashflow Yield

11.73%

AVNS Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

-1.57

AVNS Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025689.2M692.5M699.9M701.2M
2024680.1M682.4M681.5M687.8M
2023665.0M663.5M662.5M673.3M
2022603.7M588.2M576.4M703.1M
2021715.1M737.8M736.2M587.0M
2020713.8M705.3M719.6M714.8M
2019660.1M671.4M677.7M697.6M
2018622.3M634.1M648.7M652.3M
2017577.5M588.9M600.3M611.6M
2016523.3M537.6M551.9M566.2M
20151.7B1.6B1.6B509.0M
20141.7B1.7B1.7B1.7B
2013001.7B1.7B
20120001.7B
Get all data in R, Python etc through our Historical Stock Data APIs

About Avanos Medical Inc

AVNS
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy and OrthogenRx's knee osteoarthritis pain relief injection products. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEhttps://avanos.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES4044

Avanos Medical Inc Frequently Asked Questions

AVNS is the stock ticker symbol of Avanos Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Avanos Medical Inc is 637.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, AVNS's PE ratio (Price to Earnings) is -8.74 and Price to Sales (PS) ratio is 0.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVNS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Avanos Medical Inc has provided -0.069 (multiply by 100 for percentage) rate of return.